Patents by Inventor Ida Rosenkrands
Ida Rosenkrands has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210205433Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.Type: ApplicationFiled: January 22, 2021Publication date: July 8, 2021Inventors: Frank Follmann, Ida Rosenkrands, Anja Olsen, Peter Andersen
-
Patent number: 10925954Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.Type: GrantFiled: April 18, 2018Date of Patent: February 23, 2021Assignee: Statens Serum InstitutInventors: Frank Follmann, Ida Rosenkrands, Anja Olsen, Peter Andersen
-
Patent number: 10641770Abstract: The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic reagents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.Type: GrantFiled: December 15, 2014Date of Patent: May 5, 2020Assignee: Statens Serum InstitutInventors: Claus Aagaard, Søren Tetens Hoff, Ida Rosenkrands, Else Marie Agger, Peter Lawætz Andersen
-
Patent number: 10004793Abstract: The present invention is directed to a fusion protein, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion protein, antigen cocktails and immunological compositions are based on proteins secreted by the ESAT-6 secretion system 1 (ESX-1) and are among the most immunodominant M. tuberculosis (MTB) antigens.Type: GrantFiled: April 9, 2015Date of Patent: June 26, 2018Assignee: Statens Serum InstitutInventors: Claus Aagaard, Ida Rosenkrands, Truc Thi Kim Thanh Hoang, Peter Lawaetz Andersen
-
Publication number: 20170043003Abstract: The present invention is directed to a fusion protein, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion protein, antigen cocktails and immunological compositions are based on proteins secreted by the ESAT-6 secretion system 1 (ESX-1) and are among the most immunodominant M. tuberculosis (MTB) antigens.Type: ApplicationFiled: April 9, 2015Publication date: February 16, 2017Inventors: Claus Aagaard, Ida Rosenkrands, Truc Thi Kim Thanh Hoang, Peter Lawaetz Andersen
-
Publication number: 20170016897Abstract: The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic re agents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.Type: ApplicationFiled: December 15, 2014Publication date: January 19, 2017Applicant: STATENS SERUM INSTITUTInventors: Claus Aagaard, Søren Tetens Hoff, Ida Rosenkrands, Else Marie Agger, Peter Lawætz Andersen
-
Patent number: 9526773Abstract: The present invention is directed to fusion proteins, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion proteins or antigen cocktails are based on ESX secreted or associated proteins e.g. proteins secreted by the ESAT-6 secretion system 1 (ESX-1) which are among the most immunodominant M. tuberculosis (MTB) antigens.Type: GrantFiled: October 18, 2013Date of Patent: December 27, 2016Assignee: Statens Serum InstitutInventors: Claus Aagaard, Ida Rosenkrands, Truc Thi Kim Thanh Hoang, Peter Andersen
-
Publication number: 20150290311Abstract: The present invention is directed to fusion proteins, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion proteins or antigen cocktails are based on ESX secreted or associated proteins e.g. proteins secreted by the ESAT-6 secretion system 1 (ESX-1) which are among the most immunodominant M. tuberculosis (MTB) antigens.Type: ApplicationFiled: October 18, 2013Publication date: October 15, 2015Inventors: Claus Aagaard, Ida Rosenkrands, Truc Thi Kim Thanh Hoang, Peter Andersen
-
Publication number: 20140275478Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.Type: ApplicationFiled: March 17, 2014Publication date: September 18, 2014Applicant: Statens Serum InstitutInventors: Frank Follmann, Ida Rosenkrands, Anja Olsen, Peter Andersen
-
Publication number: 20130149324Abstract: Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis.Type: ApplicationFiled: February 9, 2012Publication date: June 13, 2013Applicant: Statens Serum InstitutInventors: PETER ANDERSEN, Ida Rosenkrands, Anette Stryhn
-
Patent number: 8277823Abstract: The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.Type: GrantFiled: May 21, 2010Date of Patent: October 2, 2012Assignee: Statens Serum InstitutInventors: Jesper Davidsen, Peter Andersen, Ida Rosenkrands
-
Patent number: 8241610Abstract: The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG. The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.Type: GrantFiled: April 8, 2011Date of Patent: August 14, 2012Assignee: Statens Serum InstitutInventors: Else Marie Agger, Peter Andersen, Anja Olsen, Ida Rosenkrands
-
Patent number: 8142797Abstract: Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis.Type: GrantFiled: May 21, 2010Date of Patent: March 27, 2012Assignee: Statens Serum InstitutInventors: Peter Andersen, Ida Rosenkrands, Anette Stryhn
-
Publication number: 20110250224Abstract: The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG. The total lipid extract contains both apolar lipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.Type: ApplicationFiled: April 8, 2011Publication date: October 13, 2011Applicant: Statens Serum InstitutInventors: Else Marie Agger, Peter Andersen, Anja Olsen, Ida Rosenkrands
-
Publication number: 20110020384Abstract: Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis.Type: ApplicationFiled: May 21, 2010Publication date: January 27, 2011Applicant: Statens Serum InstituteInventors: PETER ANDERSEN, Ida Rosenkrands, Anette Stryhn
-
Publication number: 20100226975Abstract: The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.Type: ApplicationFiled: May 21, 2010Publication date: September 9, 2010Applicant: Statens Serum InstitutInventors: Jesper Davidsen, Peter Andersen, Ida Rosenkrands
-
Patent number: 7749520Abstract: The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.Type: GrantFiled: July 5, 2005Date of Patent: July 6, 2010Assignee: Statens Serum InstitutInventors: Jesper Davidsen, Peter Andersen, Ida Rosenkrands
-
Publication number: 20060008519Abstract: The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.Type: ApplicationFiled: July 5, 2005Publication date: January 12, 2006Applicant: Statens Serum InstitutInventors: Jesper Davidsen, Peter Andersen, Ida Rosenkrands
-
Publication number: 20040115211Abstract: The present invention is based on the identification and characterization of a number of M. tuberculosis derived novel proteins and protein fragments (SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 17-23, 42, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72-86, 88, 90, 92, 94, 141, 143, 145, 147, 149, 151, 153, and 168-171). The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as vaccines and skin test reagents containing the polypeptides. Another part of the invention is based on the surprising discovery that fusions between ESAT-6 and MPT59 are superior immunogens compared to each of the unfused proteins, respectively.Type: ApplicationFiled: July 15, 2003Publication date: June 17, 2004Inventors: Peter Andersen, Rikke Skiot, Thomas Oettinger, Peter Birk Rasmussen, Ida Rosenkrands, Karin Weldingh, Walter Florio
-
Publication number: 20040057963Abstract: Therapeutic vaccines comprising polypeptides expressed during the latent stage of mycobacteria infection are provided, as are multiphase vaccines, and methods for treating and preventing tuberculosis.Type: ApplicationFiled: July 11, 2003Publication date: March 25, 2004Inventors: Peter Andersen, Ida Rosenkrands, Anette Stryhn